Withdrawal of Circular Regarding Inj. Cetuximab Procurement

U-25/12/165to169/2024-MedicalV कर्मचारी राज्य बीमा निगम (श्रम एवं रोजगार मंत्रालय, भारत सरकार EMPLOYEES' STATE INSURANCE CORPORATION (Ministry of Labour & Employment, Govt. of India) मुख्यालय / HEADQUARTERS पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली 110002 PanchdeepBhawan,CIG. Marg New Delht110002 www.esic. rov. in. 011-23604773dmc-rc@esc.nic.in File No.:U-25/12/165to169/2024-MedicalV (E-754406) Date:#Approved Date# To, Director (Medical) Delhi/Director (Medical) Noida Deans- AII PGIMSR's/Medical/Dental Colleges Medical Superintendents-All ESI Hospitals Dispensary In charges- Delhi/NCR/States Directors ESI Schemes- All State Circular 33 Subject: Item no. 1812 and 1813 (name-inj. Cetuximab) in DG-ESIC Rate Contract No. 167- reg. Sir/Madam, On the captioned subject, reference is invited to ESIC Hqrs Circular No. U- 25/12/165to169/2024-Medical-V (E-754406)/1 dated 02.01.2026, published on the ESIC Headquarters website vide Console No. 24046/2026 dated 02.01.2026. In this connection, it is hereby informed that the above-mentioned circular of even number stands withdrawn. Accordingly, the purchase of the drug Inj. Cetuximab may be carried out in strict adherence to Circular No. U-25/12/Action Plan/2021-MedV (e-file)/07 dated 09.01.2026, published vide Console No. 24129/2026 dated 12.01.2026 on the ESIC Headquarters website. This is for information and strictly compliance please. This issued with the approval of Competent Authority. Enclosures: As above Yours faithfully Dy. Medical Commissioner (RC/PC) Copy to:

1. All Chief Direct Demanding Officers (In-Charge) of ESIC and ESI Scheme of all States/UT's for information and strictly compliance please.

2. M/s Merck Specialities Private Limited, Godrej One, 8th Floor, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai - 400079 (Email: nitesh.sharma@merckgroup.com,trendpro@merckgroup.com) for information.

3. Website Content Manager for uploading on ESIC HQRS Website. I/3570172/2026

4. Guard File.

Dy. Medical Commissioner(RC/PC)

U-25/12/165to169/2024-MedicalV I/3570172/2026

U-25/12/165to169/2024-MedicalV कर्मचारी राज्य बीमा निगम (श्रम एवं रोजगार मंत्रालय, भारत सरकार) EMPLOYEES' STATE INSURANCE CORPORATION (Ministry of Labour & Employment, Govt. of India) File No.:U-25/12/165to169/2024-MedicalV (E-754406) To, मुख्यालय/HEADQUARTERS पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली 110002 Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 www.esic.gov.in, 011-23604773dmc-rc@esic.nic.in /0g Date:#Approved Date# Director (Medical) Delhi/Director (Medical) Noida Deans- AlI PGIMSR's/Medical/Dental Colleges Medical Superintendents-All ESI Hospitals Dispensary In charges- Delhi/NCR/States Directors ESI Schemes- All State Circular Subject: Item no. 1812 (Inj. Cetuximab-100mg) & 1813 (Inj. Cetuximab- 500mg) in DG-ESIC Rate Contract No. 167-reg. Sir/Madam, Reference is invited towards the published Rate Contract No. 167 uploaded on ESIC Hqrs website vide console no. 23712/2025 dated 12.12.2025. With reference to the captioned subject and in continuation of the above, it is hereby notified to all concerned procurement authorities that no supply order is to be placed to the DG ESIC approved Pharmaceutical firm M/s Merck Specialities Private Limited for Item no. 1812 (Inj. Cetuximab-100mg) & 1813 (Inj. Cetuximab- 500mg) in the valid DG-ESIC RC 167, till further orders. It has come to the notice of ESIC Hqrs Office that the said item is being procured by ESI Institutions via Custom Bid from GeM. Therefore, it is advised to procure the above item (Inj. Cetuximab-100mg) through GeM only and procurement through DG ESIC RC may be put on hold till further order issued by this office. This is for information and strictly compliance please. This issued with the approval of Competent Authority. Enclosures: As above Copy to: Yours faithfully Digitally signed by Sanjiv Kochhar Dy. Medic (RC/PC) 16:54:08

1. All Chief Direct Demanding Officers (In-Charge) of ESIC and ESI Scheme of all States/UT's for information and strictly compliance please. 2.M/s Merck Specialities Private Limited, Godrej One, 8th Floor, Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai - 400079 (Email: nitesh.sharma@merckgroup.com, trendpro@merckgroup.com) for information.
2. Website Content Manager for uploading on ESIC HQRS Website.
3. Guard File. 1/3431394/2026

U-25/12/ActionPlan/2021-MedV(e-file) E.S.I.C. कर्मचारी राज्य बीमा निगम (श्रम एवं रोजगार मंत्रालय, भारत सरकार) EMPLOYEES' STATE INSURANCE CORPORATION (Ministry of Labour & Employment, Govt. of India) मुख्यालय Headquarters पंचदीप भवन सीआई जी रोड, नई दिल्ली-110002 PANCHDEEP BHAWAN CIG MARG NEW DELHI-110 002 Phone: 011-23604700 Email: dir-gen@esic.nic.in Website: www.esic.nic.in/www.esic.in File No.. U-25/12/ActionPlan/2021-MedV(e-file) /07 To Director (Medical) Delhi/Director (Medical Noida Deans, All ESI PGIMSRs, Medical & Dental Colleges Medical Superintendents, All ESIC Hospitals DIMS, ESI Scheme, All States/UTs Regional Directors, ESIC-All States/UTs 09-01-2026 Subject: Clarification on Procurement of Medicines through GeM and DG- ESIC Rate Contracts-Reg. Sir/Madam, This is in reference to the Video Conference held on 24.12.2025, wherein the issue related to procurement of medicines was discussed, particularly in cases where DG-ESIC Rate Contract (RC) medicines are also available on the GeM Portal. In continuation of the deliberations held during the VC and to ensure uniformity and compliance with Government procurement procedures, it is informed that: Before procuring any medicine/item through DG-ESIC Rate Contract, concerned ESIC institutions shall generate a GeM Non-Availability Report (GeM-NAR), confirming that the said medicine/item is not available on the GeM Portal. In cases where the required RC medicine is available on the GeM Portal, the procurement shall mandatorily be carried out through the GeM Portal only, in accordance with the prevailing Government of India procurement guidelines. Any discrepancy, if observed in terms of cost, may be examined and dealt with at the local level on an item-wise basis, strictly in accordance with the provisions of the GFR and GeM Guidelines. Further, Government buyers shall ascertain the reasonableness of prices before placement of orders by using the Business Analytics (BA) tools available on the GeM Portal, including parameters such as Last Purchase Price on GeM, the Department's own Last Purchase Price, and other relevant comparative data. Incidence to be raised on GeM for abnormally high price of any medicine. It is the sole responsibility of the Dean/MS/DIMS/D(M)D/D(M)N to ensure compliance of all instructions mentioned above. This issues with the approval of the Director General, ESIC for necessary compliance. 1/3459600/2026

U-25/12/ActionPlan/2021-MedV(e-file) Yours Sincerely, Digitally signed by Sanjiv Kochhar Date: 09-01-2026 Dy. Medical Commiiss125(PC/RC Cell) Copy to:

1. Website Content Manager for uploading on ESIC HQRS Website.
2. Guard File 1/3459600/2026